<![CDATA[This work summarize multiple protective roles serum Zeaxanthin, and Malondialdehyde, in association with metabolic profiles and as a risk of retinal disorder disease with cataract, diabetes, and hypertension, totally thirty healthy control group, and seventy-five patients group for both genders were studied. Retinal disorder disease subdivided after clinical diagnosis, into three major -subgroups, the first cohort was twenty-five patients suffers of cataract, the second twenty-five of diabetic patients, while the third group is twenty-five hypertensive patients. Lipid-profile, Fasting-insulin-levels, serum zeaxanthin and malondialdehyde, have been done to all groups. Important findings presented in the roles of serum zeaxanthin, and malondialdehyde, by similarities and differences, in retinal diseases with cataract, diabetes, and hypertension. The activity levels of serum zeaxanthin in hypertensive retinopathy patients (32.80±30.56 ng/mL), was non-significantly (P>0.01) reduced compared to healthy control (88.85±139.31 ng/mL), in compression with the same patients for serum malondialdehyde MDA which expressed the highest level of MDA (2.456±2.149 μg/mL) among the rest groups, which was significantly higher (P<0.05) than that in control (0.783±0.937 μg/mL), but the differences were non-significant (P>0.05) compared to diabetic retinopathy group (1.839±1.515 μg/mL).The activity levels are negatively associated with malondialdehyde levels in retinal disease patients with cataract, diabetes, and hypertension. Retinal disease patients with cataract, diabetes, and hypertension pathogenesis aren’t legitimately ensured. But multiple protective roles may be adopted in clinical diagnosis of retina, also in response to higher levels of oxidative stress, including serum malondialdehyde, and zeaxanthin, by fasting at least eight hours pre sophisticated lens surgery.]]>
